Exhibit 99.1
Press Release | ![]() |
www.shire.com | |
Annual Information Update
April 1, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is pleased to provide its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between May 23, 2008 and March 31, 2009.
The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.
1. | Announcements made via a RIS |
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
Date | Announcement | |
31-Mar-09 | Shire and GlaxoSmithKline enter agreement to co-promote VYVANCE® (lisdexamfetamine dimesylate) CII for the treatment of adults with ADHD | |
25-Mar-09 | Publication of Shire plc’s Annual Report 2008 | |
20-Mar-09 | Shire files lawsuit against Mylan for infringement of FOSRENOL® (lanthanum carbonate) patent | |
19-Mar-09 | Notification of major interests in shares | |
16-Mar-09 | Shire files lawsuit against Barr Laboratories for infringement of FOSRENOL® (lanthanum carbonate) patents | |
16-Mar-09 | Shire withdraws European Application of for DAYTRANA™ | |
12-Mar-09 | Notification of major interests in shares | |
11-Mar-09 | Shire announces Launch of FOSRENAL® in Japan | |
09-Mar-09 | Notification of major interests in shares | |
05-Mar-09 | Notification of major interests in shares | |
02-Mar-09 | Elections for interim dividend in respect of the six months to December 31, 2008 | |
02-Mar-09 | Total Voting Rights | |
23-Feb-09 | Director/PDMR Shareholding | |
23-Feb-09 | Director/PDMR Shareholding | |
20-Feb-09 | Shire to enter European ADHD market with the acquisition of EQUASYM® IR and XL | |
20-Feb-09 | Shire Announces Opening of Office in Japan | |
19-Feb-09 | Shire delivers excellent growth for the year, with the new product portfolio achieving sales of $1bn | |
09-Feb-09 | Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan | |
09-Feb-09 | Full Year 2008 results date notification – 19 February 2009 | |
05-Feb-09 | Change to Director's details | |
02-Feb-09 | Total Voting Rights | |
05-Jan-09 | Total Voting Rights | |
17-Dec-08 | Director/PDMR Shareholding | |
01-Dec-08 | Total Voting Rights | |
25-Nov-08 | Block Listing Six Monthly Return | |
25-Nov-08 | Director/PDMR Shareholding | |
18-Nov-08 | Investor seminar | |
12-Nov-08 | Confirmation of HGT business day - 18th November 2008 | |
07-Nov-08 | Director/PDMR Shareholding |
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
05-Nov-08 | Shire successfully settles former TKT shareholder appraisal rights litigation | |
04-Nov-08 | Directors/PDMR Shareholding | |
03-Nov-08 | Total Voting Rights | |
29-Oct-08 | Shire’s new product portfolio delivers strong quarterly performance | |
15-Oct-08 | Third quarter 2008 results date notification – 29 October 2008 | |
01-Oct-08 | CHANGE OF NAME TO SHIRE PLC | |
01-Oct-08 | Total Voting Rights | |
01-Oct-08 | Notification of Acquisition of American Depository Shares by PDMR | |
25-Sep-08 | Correction - Results of the Annual General Meeting held on September 24, 2008 | |
24-Sep-08 | Results of the Annual General Meeting held on September 24, 2008 | |
23-Sep-08 | Director/PDMR Shareholding | |
12-Sep-08 | Notification of Acquisition of American Depository Shares by PDMR | |
08-Sep-08 | Notification of major interests in shares | |
01-Sep-08 | Total Voting Rights | |
01-Sep-08 | Elections for interim dividend in respect of the half year for the six months ended June, 30 2008 | |
22-Aug-08 | Notice of the 2008 Annual General Meeting and Proxy Card | |
13-Aug-08 | Shire announces holding of 81% in JERINI AG and publication of offer document | |
07-Aug-08 | Half Yearly Report | |
06-Aug-08 | Notification of Acquisition of Shares by Director/PDMR | |
06-Aug-08 | Director/PDMR Shareholding | |
04-Aug-08 | Notification of Acquisition of American Depository Shares by a Director/PDMR | |
04-Aug-08 | Director/PDMR Shareholding | |
04-Aug-08 | Notification of Acquisition of American Depository Shares by a Director/PDMR | |
31-Jul-08 | Shire delivers strong quarter: driven by $243m of new product sales. Revenue guidance upgraded. | |
30-Jul-08 | Notification of major interests in shares | |
30-Jul-08 | Notification of major interests in shares | |
24-Jul-08 | Notification of major interests in shares | |
21-Jul-08 | Robin Buchanan to step down as non-executive director on completion of term of office | |
15-Jul-08 | Jerini Receives European Commission Approval for FIRAZYR® (Icatibant) in the Treatment of HAE | |
04-Jul-08 | Second quarter 2008 results date notification - 31 July 2008 | |
03-Jul-08 | Shire to add new orphan drug to its HGT portfolio – EU launch imminent | |
01-Jul-08 | Total Voting Rights | |
19-Jun-08 | Notification of major interests in shares | |
19-Jun-08 | Director/PDMR Shareholding | |
16-Jun-08 | Notification of Acquisition of American Depository Shares by PDMR | |
11-Jun-08 | Purchase of Shares by Employee Benefit Trust | |
10-Jun-08 | Graham Hetherington appointed Chief Financial Officer and Board Director at Shire | |
01-Jun-08 | Total Voting Rights | |
28-May-08 | Purchase of Shares by Employee Benefit Trust | |
28-May-08 | Notification of major interests in shares | |
27-May-08 | Shire Announces Approval of ELAPRASE® (idursulfase) in Brazil | |
23-May-08 | Application for Listing of Shire Limited Ordinary Shares |
2. | Documents filed with the Securities and Exchange Commission (“SEC”) |
The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC’s website at www.sec.gov.
2
3. Documents filed with Companies Registry, Jersey
Date of Delivery | Document | |
27-Feb-09 | Annual return | |
01-Oct-08 | Certificate of change of name from Shire Limited to Shire plc | |
01-Oct-08 | Special resolutions passed on 24 September 2008 re: (i) authority to allot shares; (ii) authority to make market purchases of the Company's own shares (iii) change of name of the Company; and (iv) adoption of amended memorandum and articles of association of the Company to reflect the change of name | |
11-Jun-08 | Act of Court and Minute in connection with the reduction of amounts standing to the Company's share premium account. |
4. Documents sent to Shareholders
The following documents were published and sent to shareholders, and are available on the Company’s website.
Date of Delivery | Document | |
27-Mar-09 | Annual Report and Accounts for the year ended December 31, 2008 | |
27-Mar-09 | Notice of 2009 Annual General Meeting | |
22-Aug-08 | Notice of 2008 Annual General Meeting |
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.
Tony Guthrie |
Deputy Company Secretary |
For further information please contact:
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
Eric Rojas (North America) | +1 617 551 9715 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com
3